Robert Hazlett
Stock Analyst at BTIG
(0.66)
# 3,760
Out of 4,734 analysts
25
Total ratings
34.38%
Success rate
-18.65%
Average return
Main Sectors:
Stocks Rated by Robert Hazlett
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AURA Aura Biosciences | Maintains: Buy | $21 → $24 | $7.77 | +208.88% | 3 | Oct 18, 2024 | |
| NKTR Nektar Therapeutics | Assumes: Buy | $4 | $0.89 | +348.43% | 2 | Sep 30, 2024 | |
| RANI Rani Therapeutics Holdings | Maintains: Buy | $7 → $14 | $1.31 | +968.70% | 2 | May 9, 2024 | |
| LYRA Lyra Therapeutics | Maintains: Buy | $24 → $20 | $0.19 | +10,393.18% | 1 | Feb 7, 2023 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $62 → $98 | $91.94 | +6.60% | 2 | Dec 23, 2022 | |
| VSTM Verastem | Maintains: Buy | $96 → $60 | $5.33 | +1,025.70% | 3 | Oct 5, 2022 | |
| CMPS COMPASS Pathways | Initiates: Buy | $63 | $3.49 | +1,705.16% | 1 | May 27, 2021 | |
| PRTA Prothena Corporation | Upgrades: Buy | $29 | $13.77 | +110.60% | 4 | Feb 2, 2021 | |
| ITCI Intra-Cellular Therapies | Maintains: Buy | $80 → $40 | $126.20 | -68.30% | 2 | Nov 2, 2020 | |
| RDHL RedHill Biopharma | Initiates: Buy | $26,000 | $5.64 | +461,162.80% | 1 | Sep 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $26 → $6 | $2.07 | +189.86% | 2 | Sep 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $27 | $8.30 | +225.30% | 2 | Oct 16, 2017 |
Aura Biosciences
Oct 18, 2024
Maintains: Buy
Price Target: $21 → $24
Current: $7.77
Upside: +208.88%
Nektar Therapeutics
Sep 30, 2024
Assumes: Buy
Price Target: $4
Current: $0.89
Upside: +348.43%
Rani Therapeutics Holdings
May 9, 2024
Maintains: Buy
Price Target: $7 → $14
Current: $1.31
Upside: +968.70%
Lyra Therapeutics
Feb 7, 2023
Maintains: Buy
Price Target: $24 → $20
Current: $0.19
Upside: +10,393.18%
Axsome Therapeutics
Dec 23, 2022
Maintains: Buy
Price Target: $62 → $98
Current: $91.94
Upside: +6.60%
Verastem
Oct 5, 2022
Maintains: Buy
Price Target: $96 → $60
Current: $5.33
Upside: +1,025.70%
COMPASS Pathways
May 27, 2021
Initiates: Buy
Price Target: $63
Current: $3.49
Upside: +1,705.16%
Prothena Corporation
Feb 2, 2021
Upgrades: Buy
Price Target: $29
Current: $13.77
Upside: +110.60%
Intra-Cellular Therapies
Nov 2, 2020
Maintains: Buy
Price Target: $80 → $40
Current: $126.20
Upside: -68.30%
RedHill Biopharma
Sep 11, 2020
Initiates: Buy
Price Target: $26,000
Current: $5.64
Upside: +461,162.80%
Sep 4, 2020
Maintains: Buy
Price Target: $26 → $6
Current: $2.07
Upside: +189.86%
Oct 16, 2017
Maintains: Buy
Price Target: $18 → $27
Current: $8.30
Upside: +225.30%